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RESEARCH ARTICLE
Albumin Administration in Acute Ischemic
Stroke: Safety Analysis of the ALIAS Part 2
Multicenter Trial
Michael D. Hill1*, Renee H. Martin2, Yuko Y. Palesch2, Claudia S. Moy3, Diego Tamariz4,
Karla J. Ryckborst5, Elizabeth B. Jones6, David Weisman7, Creed Pettigrew8, Myron
D. Ginsberg4
1 Departments of Clinical Neurosciences, Medicine, Radiology and Community Health Sciences, Hotchkiss
Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2 Department of
Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, United States of
America, 3 Office of Clinical Research, National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, Maryland, United States of America, 4 Department of Neurology, University of
Miami Miller School of Medicine, Miami, Florida, United States of America, 5 Department of Clinical
Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 6 Department of
Emergency Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States
of America, 7 Abington Neurological Associates, Abington, Pennsylvania, United States of America,
8 Department of Neurology and Sanders-Brown Center on Aging, University of Kentucky, Lexington,




Albumin treatment of ischemic stroke was associated with cardiopulmonary adverse events
in previous studies and a low incidence of intracranial hemorrhage. We sought to describe
the neurological and cardiopulmonary adverse events in the ALIAS Part 2 Multicenter Trial.
Methods
Ischemic stroke patients, aged 18–83 and a baseline NIHSS 6, were randomized to treat-
ment with ALB or saline control within 5 hours of stroke onset. Neurological adverse events
included symptomatic intracranial hemorrhage, hemicraniectomy, neurological deteriora-
tion and neurological death. Cardiopulmonary adverse events included pulmonary edema/
congestive heart failure, acute coronary syndromes, atrial fibrillation, pneumonia and pul-
monary thromboembolism.
Results
Among 830 patients, neurological and cardiopulmonary adverse events were not differen-
tially associated with poor outcome between ALB and saline control subjects. The rate of
symptomatic intracranial hemorrhage in the first 24h was low overall (2.9%, 24/830) but
more common in the ALB treated subjects (RR = 2.4, CI95 1.01–5.8). The rate of pulmonary
edema/CHF in the first 48h was 7.9% (59/830) and was more common among ALB treated
subjects (RR = 10.7, CI95 4.3–26.6); this complication was expected and was satisfactorily
PLOS ONE | DOI:10.1371/journal.pone.0131390 September 1, 2015 1 / 13
OPEN ACCESS
Citation: Hill MD, Martin RH, Palesch YY, Moy CS,
Tamariz D, Ryckborst KJ, et al. (2015) Albumin
Administration in Acute Ischemic Stroke: Safety
Analysis of the ALIAS Part 2 Multicenter Trial. PLoS
ONE 10(9): e0131390. doi:10.1371/journal.
pone.0131390
Editor: Felix Schlachetzki, University of Regensburg,
GERMANY
Received: November 13, 2014
Accepted: May 22, 2015
Published: September 1, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: The public use data set
for this study are available through the NINDS for
general use at the following site: (http://www.ninds.
nih.gov/research/clinical_research/toolkit/archived_
datasets.htm).
Funding: This work was supported by cooperative
agreements from the National Institute of
Neurological Disorders and Stroke, National Institutes
of Health (U01NS040406, University of Miami;
U01NS054630, Medical University of South Carolina;
U01NS056975, University of Michigan;
U10NS058967, University of Kentucky).
managed with mandated diuretic administration and intravenous fluid guidelines. Troponin
elevations in the first 48h were common, occurring without ECG change or cardiac symp-
toms in 52 subjects (12.5%).
Conclusions
ALB therapy was associated with an increase in symptomatic ICH and pulmonary edema/
congestive heart failure but this did not affect final outcomes. Troponin elevation occurs rou-




High-dose human albumin was shown in pre-clinical rodent stroke models to be a highly neu-
roprotective agent.[1, 2] Albumin reduces infarction volume and cerebral edema, and improves
behavioral function, with a therapeutic window of efficacy of at least 4 hours after stroke onset.
[1, 3] Albumin normalizes the apparent diffusion coefficient within the residual infarct, relieves
obstructions in postischemic cortical venules[4], and improves microvascular hemodynamics
distal to an arterial thrombosis.[5–7]
On the basis of these and other preclinical findings, we hypothesized that high-dose albu-
min administration would improve neurological and functional outcome in patients with acute
ischemic stroke. In the Albumin in Acute Stroke (ALIAS) Pilot Clinical Trial, we first estab-
lished the dosing regimen and defined a 12–14% risk of mild-moderate pulmonary edema or
congestive heart failure as an expected adverse event of high-dose albumin therapy.[8] The
ALIAS Part 1 Trial then tested the hypothesis that 2g/kg of 25% human albumin infused intra-
venously within 5 hours of ischemic stroke onset would improve outcome measured at 90
days.[9] Enrollment in the Part 1 Trial was halted after 434 patients due to increased mortality
in the treatment arm.[8, 10] In ALIAS Part 1, congestive heart failure and pulmonary edema
were predicted safety events based upon the Pilot Trial and physiological principles of 25%
albumin (ALB) therapy. However, in both the ALIAS Pilot Trial and in ALIAS Part 1, when
congestive heart failure (CHF) or pulmonary edema occurred it was generally easily managed
with diuretic therapy. These data did not show convincingly that CHF or pulmonary edema
were directly associated with early increased mortality, but there were more observed cardio-
pulmonary adverse events in the ALB group.[11] After an unblinded analysis of the Part 1
safety data, the trial was restarted as ALIAS Part 2 with stringent new inclusion and exclusion
criteria and safety monitoring.[12] The Part 2 Trial was stopped early because of futility on the
recommendation of the Data Safety and Monitoring Board (DSMB) after 841 (of a planned
N = 1100) subjects had been enrolled.[13]
Stroke is associated with secondary and immediate changes in cardiac function. Changes on
electrocardiogram, such as T-wave inversion, are commonly associated with hemorrhagic
forms of stroke, but may also be seen with ischemic stroke.[14] Troponin elevations in the first
hours after ischemic stroke have been documented in up to 20% of patients in recent hospital-
based cohorts.[15, 16] This relationship is observed more commonly among patients with
hypertension, chronic renal disease, atrial fibrillation, congestive heart failure, and coronary
Albumin Administration in Ischemic Stroke: Safety Analysis
PLOS ONE | DOI:10.1371/journal.pone.0131390 September 1, 2015 2 / 13
Competing Interests: The authors have declared
that no competing interests exist.
artery disease, but elevated troponins are only variably associated with stroke outcome.[17–19]
Similarly, troponin elevations have been documented after carotid artery stenting and are a
marker of poorer long-term prognosis.[20] After intracerebral hemorrhage, troponin eleva-
tions and minor cardiac events have been documented.[21] Typically, the degree of troponin
elevation is small and not associated with either electrocardiographic changes or clinical symp-
toms such as congestive heart failure.
We report a detailed analysis of the safety results of the ALIAS Part 2 Trial in an attempt to
further understand the neutral results of the trial, to explore brain-heart interactions in acute
stroke and to examine the role of colloid administration in the acute treatment of stroke.
Methods
Informed consent for enrolment into the trial was provided by all participants or their legally
authorized surrogate decision-maker. The following institutions' IRB (or Research Ethics
Board) approved the trial protocol: Arizona—University of Arizona Medical Center—South
Campus, Tucson, AZ Arizona—University of Arizona Medical Center, Tucson, AZ; Atlantic
Neuroscience Institute, Overlook Hospital Baylor College of Medicine; Buffalo General Medi-
cal Center; Centre de Sante et de Service Sociaux de Chicoutimi Centre de recherche de hopital
Charles LeMoyne; Chaim Sheba Medical Center at Tel-Hashomer; Cincinnati—Bethesda
North Hospital, Cincinnati, OH; Cincinnati—Christ Hospital, Cincinnati, OH; Cincinnati—
Good Samaritan Hospital Cincinnati—Mercy Health Fairfield Hospital, Fairfield, OH; Cincin-
nati—St. Elizabeth Hospital, Florence, KY; Cincinnati—St. Elizabeth Medical Center South,
Edgewood, KY; Cincinnati—University Hospital, Cincinnati, OH; Duke University Medical
Center; Emory—Emory University Hospital, Atlanta, GA; Emory—Grady Memorial Hospital,
Atlanta, GA; Foothills Hospital, University of Calgary; Grey Nuns Community Hospital;
HFHS—Henry Ford Hospital, Detroit, MI; Hadassah Medical Organization, Hadassah; Uni-
versity Hospital HealthEast Care System St. Josephs Hospital Helsinki; University Central Hos-
pital Intercoastal Neurology-Intercoastal Medical Research Center Jackson Memorial Hospital,
University of Miami; John Muir Medical Ctr-Concord John Muir Medical Ctr-Walnut Creek;
Kentucky—University of Kentucky Hospital, Lexington, KY; London Health Sciences Centre-
University Hospital; Loyola University Medical Center; Maryland—University of Maryland
Medical Center, Baltimore, MD; Maryland—Upper Chesapeake Medical Center, Bel Air, MD;
Mayo Clinic Hospital, Phoenix, AZ; Mercy Hospital of Buffalo; MetroHealth Medical Center
Minnesota—Fairview Southdale Hospital, Edina, MN; Minnesota—Hennepin County Medical
Center, Minneapolis, MN; Minnesota—University of Minnesota Medical Center Fairview,
Minneapolis, MN; NYP—NYP Columbia University Medical Center, New York, NY; NYP—
New York Methodist Hospital, Brooklyn, NY; NYP—Winthrop University Hospital, Mineola,
NY; Neuroscience Research Institute at Florida Hospital Orlando; OHSU—Providence Port-
land Medical Center; OHSU—Providence St. Vincent Medical Center; OHSU Legacy Emman-
uel Hospital; Ohio State University Medical Center; Oregon Health and Science University,
Portland; Queen Elizabeth II Health Science Centre; Rambam Health Care Campus; Royal
Inland Hospital, Kamloops, BC; Sacred Heart Medical Center Saint Louis University; Seton
Medical Center; Soroka Medical Center; Stanford—El Camino Hospital, Mountain View, CA;
Stanford—O'Connor Hospital, San Jose, CA; Stanford—Stanford University Medical Center,
Palo Alto, CA; Tampere University Hospital Tel-Aviv; Sourasky Medical Center; Temple—
Hahnemann University Hospital, Philadelphia, PA; Temple—Penn State Hershey
Medical Center, Hershey, PA; Temple—Temple University Hospital, Philadelphia, PA;
Texas—Memorial Hermann Texas Medical Center, Houston, TX; The Ottawa Hospital Thun-
der Bay Regional Health Sciences Centre; Trillium Health Centre; UCLA-Santa Monica;
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UCSF—California Pacific Medical Center Davies Campus, San Francisco, CA; UCSF—Califor-
nia Pacific Medical Center Pacific Campus, San Francisco, CA; UCSF—San Francisco General
Hospital, San Francisco, CA; UCSF—UCSF Medical Center, San Francisco, CA; UPenn—
Abington Memorial Hospital, Abington, PA; UPenn—Christiana Hospital, Newark, DE; Uni-
versity of Alberta; University of Florida/Shands Jacksonville; University of North Carolina at
Chapel Hill; University of Pennsylvania Medical Center; University of Pittsburgh Medical Cen-
ter; University of Toronto, St. Michaels Hospital; VCU—VCUMedical Center, Richmond,
VA; Vancouver General Hospital Stroke Program; Villages Research Group Wake Med Health
and Hospitals; Wayne—Detroit Receiving Hospital, Detroit, MI; Wayne—Sinai-Grace Hospi-
tal, Detroit, MI; Wayne—William Beaumont Hospital, Royal Oak, MI; Wisconsin—Froedtert
Memorial Lutheran Hospital, Milwaukee, WI; Yale University School of Medicine, New
Haven, CT.
The Albumin in Acute Stroke (ALIAS) Part 2 Trial was a placebo-controlled, double-blind,
phase 3 multicenter clinical trial with the primary objective to ascertain whether a weight-
adjusted intravenous infusion of 25% albumin solution begun within 5 hours of stroke onset
would increase the proportion of subjects with a favorable outcome at 90 days from randomi-
zation, compared to subjects treated with a similar volume of isotonic saline, over and above
the current best standard of care.[9, 13] A favorable primary outcome was defined as either a
modified Rankin Scale (mRS) score of 0 or 1 or a National Institutes of Health Stroke Scale
(NIHSS) score of 0 or 1, or both. A centralised web-based randomisation process assigned sub-
jects 1:1 to either albumin or saline via a minimisation-plus-biased-coin algorithm that
accounted for the current status of treatment group balance within and across sites. We used
multiple methods to ensure the effectiveness of blinding including blinded treatment kits,
opaque IV kit covering, and 90-day outcome assessment by a blinded observer.
Adult patients aged 18 through 83 with ischemic stroke and baseline NIHSS score 6 were
randomized and treated within 5 hours of stroke onset. Age 83 years was a data-driven upper
limit based upon the ALIAS Part 1 study.[22] Subjects were treated intravenously with 25%
human albumin (2 g per kg estimated body weight) infused over 2 hours. Control subjects
received a comparable volume of isotonic saline. Vital signs were monitored frequently. The
following data were monitored and collected: serum chemistry, ECG and intravenous fluid
intake at 24 and 48 hours, brain CT or MRI at 24 hours, neurological and cardiac status includ-
ing NIHSS at 24 and 48 hours and at 7 days or discharge, whichever came first. Patients with
elevated baseline troponin levels or baseline abnormal ECG findings suggesting cardiac ische-
mia were excluded per protocol. Patients at risk for CHF episode or exacerbation were also
excluded—those with CHF in the last 6 months, severe aortic or mitral stenosis, cardiac surgery
in the last 6 months, acute myocardial infarction (AMI) in the last 3 months, signs or symp-
toms of current AMI, any physical exam finding suggestive of CHF, hemodynamically signifi-
cant arrhythmias, evidence of CHF on chest X-ray (if obtained), creatinine> 2.0 mg/dL or
elevated baseline troponin (>0.1 μg/L).
Intravenous fluid management and diuretic administration were mandated. Subjects were
not to receive total intravenous fluids in excess of 4200 ml during the first 48 hours, including
the volumes of study drug and thrombolytic agent (if used). For subjects exceeding this
amount, site investigators were required to provide justifications, which were centrally adjudi-
cated as to clinical reasonableness. Subjects were also required to receive a single dose of furose-
mide 20 mg IV (or an equivalent loop diuretic), between 12 and 24 hours after study-drug
administration. Physicians withholding diuretics were asked to provide a written justification.
Antiplatelet therapy was recommended in all subjects within 48 hours of their stroke. Blood
pressure was managed according to the local standard of care.
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Eligible patients received intravenous tPA within standard time windows according to local
guidelines. If available at the site and clinically routine, endovascular treatment (intra-arterial
tPA and/or endovascular thrombectomy) was permitted within the trial protocol.
Safety event reports were reviewed internally by the study team blinded to treatment alloca-
tion for completeness. All serious adverse events were adjudicated for unexpectedness and
relatedness to the study treatment by the site PI and by two external safety monitors who
remained blinded to treatment allocation. Adverse events were subsequently reviewed by the
unblinded DSMB statistician on a monthly basis and by the trial’s DSMB, initially on a quar-
terly basis and then every six months. This heightened degree of safety monitoring was imple-
mented because of the results of ALIAS Part 1. ECGs were adjudicated both at the site level and
centrally and troponin levels were re-measured at 24–48 hours. Brain imaging was reviewed
centrally by a 2-reader panel consisting of a neuroradiologist and neurologist. Scans (primarily
CT but some MRI) were scored for baseline stroke severity using the ASPECTS score, and the
24-hour scans for hemorrhage and infarct size.
We defined common stroke-related expected adverse events per protocol. Symptomatic
intracranial hemorrhage was defined as a new intracranial hemorrhage causally associated with
deterioration in neurological status as determined by the treating physician. It was considered
related to acute thrombolytic treatment if it occurred in the first 24 hours after treatment. Pul-
monary edema or congestive heart failure was defined as any evidence of pulmonary compro-
mise associated with physical examination signs of fluid overload. We defined pulmonary
edema/congestive heart failure at five levels: 1) asymptomatic—subject requires no additional
therapy; pulmonary congestion noted on chest X-ray only, 2) mild—subject requires and
responds to a single dose of diuretic (20mg intravenous furosemide or equivalent) and requires
supplemental oxygen by nasal prongs only, 3) moderate—subject requires more than a single
dose of diuretic but responds and requires supplemental oxygen by nasal prongs only, 4) severe
—the subject requires treatment with multiple doses of a diuretic, supplemental oxygen
via face mask, or additional problems arise such as cardiac arrhythmias or a requirement for
cardiac telemetry, 5) life-threatening—the subject requires intubation or non-invasive BiPAP/
CPAP to manage significant hypoxemia. Levels 3–5 were automatically reported as SAEs. Tro-
ponin elevation was defined as any troponin level greater than 0.1 μg/L.
Prior to the commencement of the ALIAS Part 2 Trial, we assessed the Virtual International
Stroke Trials Archive (VISTA) data set[23] to examine for evidence of congestive heart failure
among stroke patients in previous stroke trials. The VISTA data were accessed in June 2006, at
which time 5 placebo-controlled trials had adequate reportable information on CHF as an
adverse event. Three trials used a saline placebo and 2 used a non-saline placebo. In these trials,
the dose of saline or vehicle used was 500 ml/day in contrast to the ALIAS dose which was
up to 750ml of study drug/saline over 2h. We assessed for the occurrence of CHF and evaluated
predictors of CHF from the existing data.
Role of funding source
The trial was funded by the U.S. National Institutes of Health/National Institute of Neurologi-
cal Disorders and Stroke. A representative of NINDS (CSM) participated in study design, man-
agement and interpretation. Baxter Healthcare Corporation provided funds to extend the trial
to Finland but played no role in the design, execution, or interpretation of the study.
Statistical Methods
The safety sample (n = 830) was defined a priori and consisted of all subjects who received at
least 20% of the calculated dose of study drug. This differed from the intention-to-treat (ITT)
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sample by 11 patients. Data are reported using standard descriptive statistics. Adjusted esti-
mates of effect size were produced using generalized linear models log link to directly calculate
the rate ratios. In the analysis of the VISTA data, we used multiple logistic regression and effect
size estimates are presented as odds ratios. Each test was conducted using two-sided
alpha = 0.05. We made no adjustment for multiplicity of testing. All analyses presented are
hypothesis-generating.
Results
841 subjects from U.S. (69 sites), Canada (13 sites), Finland (2 sites), and Israel (5 sites) were
randomized to the trial from February 2009 to September 2012. Baseline characteristics were
similar between treatment and control arms (Table 1). The median doses were 632 ml (IQR
181ml) albumin, and 640ml (IQR 176ml) 0.9% saline, infused over 2 hours.
Major neurological adverse events occurring in the trial were intracranial hemorrhage,
hemicraniectomy, neurological deterioration, and neurological death (Table 2). The rate of
symptomatic intracranial hemorrhage was low (2.9%, 24/830) but more common in the ALB-
treated subjects (RR = 2.4, CI95 1.01–5.8). Symptomatic ICH occurred in only 1 subject in the
non-thrombolysis group. The increase in symptomatic hemorrhage was paralleled by imaging
analysis with PH-2 type hemorrhage occurring more commonly in the ALB group (RR = 2.8,
CI95 1.01–7.7). Asymptomatic hemorrhage and neurological deterioration were not more com-
mon in the ALB group. Hemicraniectomy was uncommon but was numerically more common
in the ALB group. Symptomatic ICH was not associated with increased death. Neurological
adverse events did not show significant impact on overall primary outcome at 90 days
(Table 3).
Table 1. Baseline and Treatment Characteristics of the Subjects in Safety Sample.
Albumin (N = 416) Saline Control
(N = 414)
Demographics
Age (mean, SD) 63.5 (12.9) 64.9 (12.9)
Sex, male (%, n) 52.9% (220) 56.0% (232)
Caucasian† (%,n) 74.5% (310) 72.8% (302)
Black† (%, n) 16.1% (67) 20.3% (83)
Asian† (%, n) 6.0% (25) 4.8% (20)
Medical History
Hypertension 71.9% (299) 70.5% (292)
Atrial fibrillation 18.8% (78) 18.6% (77)
Past congestive heart failure 4.1% (17) 6.3% (26)
Past myocardial infarction 10.6% (44) 12.1% (50)
Past stroke 20.9% (87) 18.6% (77)
Past transient ischemic attack 12.3% (51) 11.8% (49)
Diabetes mellitus 18.5% (77) 22.5% (93)
Hyperlipidemia 46.6% (194) 51.0% (211)
Peripheral vascular disease 5.0% (21) 6.0% (25)
Clinical Factors
NIHSS score‡ (median, iqr) 10 (9) 11 (9)
ASPECTS§ > 7 (%, n/N) 77.4% (319/412) 78.0% (323/410)
OCSP** clinical stroke type
(Continued)
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Cardiopulmonary adverse events were more common in the ALB arm (Table 4). Any
congestive heart failure or pulmonary edema in the first 48 hours was 10-fold more likely. The
absolute rate (13.0%) was identical to that observed in the ALIAS Pilot Trial (13.4%) and in
ALIAS Part 1 (12.1%).[8, 22] In the saline group, congestive heart failure or pulmonary edema
occurred in 1.2% of patients. As in the prior ALB trials, CHF or pulmonary edema was gener-
ally easily managed with diuretics without the need for more invasive measures such as intuba-
tion or intensive care unit admission. We also observed greater proportions of atrial fibrillation
Table 1. (Continued)
Albumin (N = 416) Saline Control
(N = 414)
TACS 24.3% (101) 23.4% (97)
PACS 55.3% (230) 56.0% (232)
LACS 12.0% (50) 11.1% (46)
POCS 8.4% (35) 9.4% (39)
Thrombolysis 83.2% (346) 86.0% (356)
Intravenous tPA* only 66.6% (277) 69.8% (289)
Intravenous tPA* plus any endovascular procedure 16.6% (69) 16.2% (67)
Any endovascular procedure only 5.8% (24) 2.9% (12)
No thrombolysis 11.1% (46) 11.1% (46)
Systolic BP¶, mm Hg (mean, SD) 155 (28) 157 (30)
Glucose, mmol/L (mean, SD) 7.1 (2.5) 7.7 (3.7)
Hemoglobin, g/L (mean, SD) 139 (17) 140 (18)
Creatinine, μmol/L (mean, SD) 86.3 (23.1) 90.3 (26.9)
ECG¶ at baseline shows normal sinus rhythm (%,n) 72.3% (297) 72.9% (296)
Process Measures
Stroke onset to initiation of study drug infusion (min)
[median, iqr]
200 (82) 198 (75)
Stroke onset to initiation of intravenous tPA (min)[median,
iqr]
126 (71) 131 (68)
Initiation of IV tPA to initiation of study drug infusion (min)
[median, iqr]
60 (31) 60 (32)
Post-treatment–Fluids and Cardiac Status
Total IV fluids administered within 48 hours of





ECG¶ at 24 hours shows normal sinus rhythm (%, n) 70.3% (275) 78.3% (313)
* tPA = tissue plasminogen activator
** OCSP = Oxfordshire Community Stroke Project stroke classification (TACS = total anterior circulation
syndrome; PACS = partial anterior circulation syndrome; LACS = lacunar syndrome; POCS = posterior
circulation syndrome)
¶BP = blood pressure; IV = intravenous; ECG = electrocardiogram
† Race and ethnic group were self-reported.
‡ The National Institutes of Health Stroke Scale (NIHSS) is a 42-point scale that quantifies neurological
deficits in 11 categories, with 0 indicating normal function without deficits, and higher scores indicating
greater severities of deficit.
§ The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) uses computed
tomography to assess 10 regions of the brain; a score of 1 indicates a normal region and 0 indicates a
region showing signs of ischemia. Total scores range from 10 (no evidence of early ischemia) to 0 (all 10
regions of the affected hemisphere show early ischemic changes).
doi:10.1371/journal.pone.0131390.t001
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and troponin elevation within 48 hours. Troponin elevation without ECG change or cardiac
symptoms occurred in 52 subjects (12.5%), of whom 21 developed pulmonary edema or CHF.
Acute coronary syndromes occurred infrequently and were associated with troponin elevation.
Symptomatic ICH was also associated with a greater occurrence of troponin elevation, atrial
fibrillation, pneumonia, and pulmonary embolus but not acute coronary syndromes (S1
Table).
Cardiopulmonary adverse events were associated with a substantial need for intensive care
admission, prolongation of hospital stay and/or operative intervention (Table 4). This was gov-
erned by the adverse event and was not differentially distributed by ALB vs. saline control
treatment. No cardiopulmonary adverse events were convincingly associated with the primary
outcome or with increased death (Table 3). Symptomatic ICH was numerically associated with
poorer outcome, and the direction of effect of cardiopulmonary adverse effects was similarly
towards a poorer outcome, but the confidence intervals were broad.
In the VISTA data set of 4,484 patients, median age was 72 (IQR 16) and 47.5% were female.
(S2 Table). The majority of patients suffered ischemic stroke (89.5%) with a smaller proportion
of ICH (9.4%) and other/non-ischemic (1.1%) final diagnoses. All patients had an onset-to-
treatment time of within 12 hours and had been randomized to and received placebo or con-
trol. A total of 2,794 (62%) of patients received a saline control. In 895 patients who received
saline control, the amount received was 120 ml acutely with standard-of-care intravenous flu-
ids over the next 5 days; in the remainder the total dose is not known. In the non-saline control
group (n = 1690, 38%), all patients received 250 ml loading over 30 minutes followed by 250
ml over 3.5 hours and a daily dose of 150 ml for 5 days. An episode of any congestive heart fail-
ure occurred in 52 (1.1% CI95 0.9–1.5) patients. Of these 52, data on the timing of CHF were
available in 34, and among these 34, 26 (76%) occurred during the first week after enrolment.
Table 2. Neurological adverse events.
Outcome Albumin(N = 416)%(n) Saline Control(N = 414)%(n) Risk Ratio (CI95)
Symptomatic ICH1 ANY 6.7 (28) 3.1 (13) 2.1 (1.1–4.1)
Symptomatic ICH1 within 24 hours 4.1 (17) 1.7 (7) 2.4 (1.0–5.8)
Asymptomatic ICH1 ANY 11.1 (46) 8.7 (36) 1.3 (0.8–1.9)
Asymptomatic ICH1 within 24 hours 6.5 (27) 5.6 (23) 1.2 (0.7–2.0)
ICH by Type2
HI-1 12.5 (51) 15.3 (62) 0.8 (0.6–1.2)
HI-2 3.2 (13) 3.5 (14) 0.9 (0.4–1.9)
PH-1 2.0 (8) 1.2 (5) 1.6 (0.5–4.8)
PH-2 3.4 (14) 1.2 (5) 2.8 (1.0–7.7)
rPH 1.2 (5) 1.0 (4) 1.2 (0.3–4.6)
Neurological Deterioration within 48 hours 11.3 (47) 9.7 (40) 1.2 (0.8–1.7)
Hemicraniectomy within 7 days 2.9 (12) 1.5 (6) 2.0 (0.8–5.3)
Neurological Death within 7 days 3.1 (13) 3.1 (13) 1.0 (0.5–2.1)
Neurological Death within 30 days 5.1 (21) 6.0 (25) 0.8 (0.5–1.5)
Neurological Death within 90 days 5.3 (22) 6.3 (26) 0.8 (0.5–1.5)
1ICH = intracranial hemorrhage
2HI1 = hemorrhagic infarction type 1; HI2 = hemorrhagic infarction type 2; PH1 = parenchymal hematoma type 1; PH2 = parenchymal hematoma type2;
rPH = remote parenchymal hematoma
Note: There are 18 subjects without a 24 hour centrally read CT such that the denominator for the Albumin group is 407 and for the Saline group is 405.
doi:10.1371/journal.pone.0131390.t002
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Multivariable analysis using the complete VISTA data set showed that age (OR 1.1 per year
CI95 1.01–1.1), hypertension (OR 3.6, CI95 1.5–8.5) and saline administration (OR 5.4, CI95
2.1–13.7) were predictive of CHF. Only about half the population had available baseline
NIHSS scores available. In a model using patients with NIHSS data, multivariable analysis of
this population showed that stroke severity defined by NIHSS (OR 1.1 per point increase, CI95
1.01–1.10), age (OR 1.1 per year, CI95 1.01–1.1) and saline treatment (OR 10.3, CI95 3.9–27.3)
were predictors of CHF. No significant interactions were observed in either model.









Pulmonary edema/CHF1 ANY 1.3 (0.5–2.9) 1.1 (0.5–2.5) 1.0 (0.8–1.3) 1.0 (0.7–1.3)
Pulmonary edema/CHF1 within 48
hours
0.8 (0.2–2.5) 0.6 (0.1–1.7) —- —-
Acute coronary syndromes ANY 0.9 (0.2–2.9) 0.9 (0.2–2.8) 1.0 (0.6–1.5) 1.0 (0.7–1.3)
Acute coronary syndromes Within 48
hours
1.2 (0.1–8.4) 0.6 (0.08–4.1) 1.1 (0.5–2.0) 1.0 (0.6–1.5)
Troponin leak ANY1 0.8 (0.3–1.8) 0.7 (0.3–1.6) 1.0 (0.7–1.3) 1.0 (0.7–1.2)
Troponin leak Within 48 hours 0.7 (0.3–1.5) 0.6 (0.3–1.4) 1.0 (0.7–1.3) 1.0 (0.7–1.3)
Atrial fibrillation ANY *** *** 1.1 (0.9–1.3) 1.0 (0.8–1.2)
Atrial fibrillation within 48 hours 2.4 (0.7–7.4) 2.1 (0.7–6.3) 1.0 (0.8–1.2) 1.0 (0.7–1.3)
Pneumonia ANY 1.7 (0.3–8.1) 1.8 (0.3–8.6) 1.0 (0.7–1.3) 1.0 (0.8–1.2)
Pneumonia within 7 days 2.2 (0.2–18.6) 2.3 (0.2–18.7) 1.1 (0.8–1.5) 1.0 (0.8–1.3)
Shortness of breath ANY 2.0 (0.5–7.5) 1.3 (0.3–4.7) —- —-
Shortness of breath within 7 days —- —- —- —-
Pneumonia or shortness of breath
ANY
1.8 (0.6–5.3) 1.8 (0.6–5.3) 1.0 (0.8–1.2) 1.0 (0.8–1.2)
Pneumonia or shortness of breath
within 7 days
4.1 (0.5–30.7) 3.9 (0.5–29.3) 1.1 (0.8–1.4) 1.0 (0.8–1.2)
Pulmonary embolus ANY —- —- —- —-
Pulmonary embolus within 7 days —- —- —- —-
Symptomatic ICH2 ANY 0.5 (0.1–2.0) 0.4 (0.09–1.7) 0.8 (0.5–1.3) 0.9 (0.7–1.2)
Symptomatic ICH2 within 24 hours 0.2 (0.02–1.9) 0.2 (0.02–1.9) 0.9 (0.4–2.0) 1.0 (0.6–1.4)
Asymptomatic ICH2 ANY 1.0 (0.5–2.0) 1.1 (0.5–2.1) *** 0.9 (0.6–1.3)
Asymptomatic ICH2 within 24 hours 1.1 (0.4–2.8) 1.0 (0.4–2.4) —- —-
Central Imaging ICH2 by Type
HI-13 —- —- 1.0 (0.8–1.2) 1.0 (0.8–1.1)
HI-23 0.7 (0.1–3.6) 0.7 (0.1–3.3) 0.9 (0.6–1.2) 0.9 (0.6–1.3)
PH-13 1.3 (0.1–10.5) 1.0 (0.1–8.1) 1.5 (0.6–3.1) 1.1 (0.6–1.9)
PH-23 0.4 (0.02–4.7) 0.4 (0.03–5.2) 1.6 (0.5–5.0) 1.2 (0.7–1.9)
rPH3 1.6 (0.2–11.9) 2.0 (0.2–13.8) —- —-
Neurological deterioration within 48
hours
0.9 (0.05–13.2) 0.8 (0.05–12.5) 1.0 (0.7–1.4) 1.0 (0.8–1.2)
Hemicraniectomy within 7 days —- —- 0.9 (0.5–1.5) 0.9 (0.6–1.4)
1CHF = congestive heart failure
2ICH = intracranial hemorrhage
3HI1 = hemorrhagic infarction type 1; HI2 = hemorrhagic infarction type 2; PH1 = parenchymal hematoma type 1; PH2 = parenchymal hematoma type2;
rPH = remote parenchymal hematoma–according to the ECASS-3 classification of hemorrhage[28]
*Adjusted for age, sex, baseline NIHSS score
doi:10.1371/journal.pone.0131390.t003
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Discussion
Some adverse events, neurological and cardiopulmonary, were more common in the ALB
group compared to saline control. None of these adverse events was substantively associated
with the primary outcome at 90 days in the ALIAS Part 2 Trial.
The increase in symptomatic ICH, although small, was entirely unexpected. A priori, we
had hypothesized the ALB would be protective against ICH because of its potential role as a
microcirculation reperfusion agent, blood-brain barrier protectant and anti-oxidant.[24] The
increase may be associated with effects on the coagulation system. Hydroxyl-ethyl starch and
albumin are associated with a mild coagulopathy, possibly related to hemodilution of coagula-
tion factors and by binding of calcium.[25, 26] Albumin causes smaller ex-vivo clot formation
and less stable clots.[26, 27] Thus, it is plausible that high-dose albumin is a mild antithrombo-
tic agent.
Pulmonary edema/congestive heart failure was an expected consequence of ALB therapy
and occurred at the same absolute rate as predicted by the ALIAS Pilot Trial and ALIAS Part 1
Trial. Albumin administration most likely resulted directly in intravascular volume expansion,
increased pre-load and increased myocardial wall-stress. In predisposed patients, possibly
those with pre-existing coronary artery disease or reduced cardiac function, this resulted in an
increased incidence of cardiopulmonary adverse events. However, the large majority of occur-
rences of fluid overload manifesting as congestive heart failure and pulmonary edema were eas-
ily managed with diuretics and fluid restriction in the first 48 hours.
In addition, symptomatic ICH was associated with troponin elevations. Because we
excluded patients with baseline troponin elevations [1.2% (10/830) had baseline troponin
Table 4. Cardiopulmonary adverse events.
Outcome Albumin (N = 416)
%(n)
Saline Control
(N = 414) %(n)
Risk Ratio
(CI95)
Prolonged hospital stay or operative
intervention due to AE %(n/N)
Pulmonary edema/CHF* ANY 14.4 (60) 4.6 (19) 3.1 (1.9–5.2) 18% (14/79)
Pulmonary edema/CHF* within 48
hours
13.0 (54) 1.2 (5) 10.7 (4.3–
26.6)
19% (11/59)
Acute coronary syndromes ANY 4.1 (17) 2.2 (9) 1.9 (0.8–4.2) 46% (12/26)
Acute coronary syndromes Within
48 hours
2.4 (10) 1.0 (4) 2.5 (0.8–7.9) 21% (3/14)
Troponin leak ANY 12.5 (52) 4.6 (19) 2.7 (1.6–4.5) 17% (12/71)
Troponin leak within 48 hours 12.3 (51) 3.9 (16) 3.2 (1.8–5.5) 16% (11/67)
Atrial fibrillation ANY 12.0 (50) 8.5 (35) 1.4 (0.9–2.1) 8% (7/85)
Atrial fibrillation within 48 hours 7.7 (32) 4.6 (19) 1.7 (0.9–2.9) 7% (3/41)
Pneumonia ANY 11.1 (46) 7.5 (31) 1.5 (0.9–2.3) 23% (18/77)
Pneumonia within 7 days 8.2 (34) 4.6 (19) 1.8 (1.0–3.1) 23% (12/53)
Shortness of breath ANY 2.9 (12) 1.9 (8) 1.5 (0.6–3.6) 25% (4/20)
Shortness of breath within 7 days 2.2 (9) 0.7 (3) 3.0 (0.8–
10.9)
17% (2/12)
Pneumonia or shortness of breath
ANY
13.7 (57) 9.2 (38) 1.5 (1.0–2.2) 23% (22/95)
Pneumonia or shortness of breath
within 7 days
10.3 (43) 5.3 (22) 1.9 (1.2–3.2) 21% (14/65)
Pulmonary embolus ANY 1.7 (7) 1.2 (5) 1.4 (0.4–4.4) 33% (4/12)
Pulmonary embolus within 7 days 0.5 (2) 0.0 (0) 1 50% (1/2)
*CHF = congestive heart failure
doi:10.1371/journal.pone.0131390.t004
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elevation> 0.1 μg/L], we likely selected a group of stroke patients at lowest risk for cardiac
complications. Prior studies have suggested that patients with elevated troponin levels at base-
line have a higher prevalence of co-morbid cardiac conditions, most commonly atrial fibrilla-
tion. Nevertheless, the increase in troponin that occurred in association with ICH is
concordant with other studies showing a link between stroke and sub-clinical cardiac ischemia.
We did not observe a relative increase in the frequency of ICH over the course of the trial, but
the increased occurrence of ICH in the ALB group is a component cause of the overall increase
in cardiopulmonary adverse events in the trial.
If we assume that infusion of an average of 640 ml of saline over 2 hours can be considered a
standard treatment and examine the control group, then the occurrence of cardiopulmonary
events in ischemic stroke patients is not trivial. Between 1 and 5% of patients have a cardiopul-
monary outcome in the first 48 hours and nearly double that over 90 days. The analysis of the
VISTA data set adds further credence to the observation that CHF is not a rare event after
stroke. Further, we present the intriguing possibility that treatment with saline is not necessar-
ily an inactive placebo. In the VISTA data set, we provide evidence that saline administration
was associated with the development of CHF as an adverse event. Nevertheless, it is clear that
the oncotic effect of 25% albumin resulted in a greater degree of fluid overload compared to
saline alone. It remains possible that adverse events counterbalanced any potential treatment
effect, such that the overall effect of ALB treatment was neutral.
Overall, cardiopulmonary events are relatively common among ischemic stroke patients.
Our study is likely to have underestimated the common population rate of such events because
we specifically excluded patients with high-risk cardiac status. The ALIAS-2 Trial adds to the
existing literature on the brain-heart interaction in the acute phase of illness.
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